Alzheimer's disease: future drug development and the blood-brain barrier

[11] ABBY A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease [J]. NEUROLOGY, 2018, 90 (21) : E1889 - E1897

[12] Erythropoietin therapy for acute stroke is both safe and beneficial [J]. MOLECULAR MEDICINE, 2002, 8 (08) : 495 - 505

[13] Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle [J]. Fluids and Barriers of the CNS, 8 (1)

[14] Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial [J]. ORPHANET JOURNAL OF RARE DISEASES, 2018, 13

[15] ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) : 885 - 890

[16] Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment [J]. RADIOLOGY, 2016, 281 (01) : 99 - 108

[17] Logovinsky V, 2016, ALZHEIMERS RES THER, V8, DOI [10.1186/s13195-016-0181-2, 10.1016/j.trci.2016.01.001]

[18] Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (12): : 1571 - 1577

[19] Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial [J]. MOLECULAR THERAPY, 2019, 27 (02) : 456 - 464

[20] Are antibodies directed against amyloid- (A) oligomers the last call for the A hypothesis of Alzheimer's disease? [J]. IMMUNOTHERAPY, 2019, 11 (01) : 3 - 6

[11] ABBY A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease [J]. NEUROLOGY, 2018, 90 (21) : E1889 - E1897

[12] Erythropoietin therapy for acute stroke is both safe and beneficial [J]. MOLECULAR MEDICINE, 2002, 8 (08) : 495 - 505

[13] Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle [J]. Fluids and Barriers of the CNS, 8 (1)

[14] Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial [J]. ORPHANET JOURNAL OF RARE DISEASES, 2018, 13

[15] ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) : 885 - 890

[16] Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment [J]. RADIOLOGY, 2016, 281 (01) : 99 - 108

[17] Logovinsky V, 2016, ALZHEIMERS RES THER, V8, DOI [10.1186/s13195-016-0181-2, 10.1016/j.trci.2016.01.001]

[18] Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (12): : 1571 - 1577

[19] Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial [J]. MOLECULAR THERAPY, 2019, 27 (02) : 456 - 464

[20] Are antibodies directed against amyloid- (A) oligomers the last call for the A hypothesis of Alzheimer's disease? [J]. IMMUNOTHERAPY, 2019, 11 (01) : 3 - 6